{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T11:23:40Z","timestamp":1789298620483,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Acute graft-versus-host disease (aGVHD) as complication after allogeneic hematopoetic stem cell transplantation (allo-HSCT) occurs in up to 70% of patients. The survival prognosis depends on the severity of GVHD and response to first-line therapy. In patients who are refractory to both, steroids and ruxolitinib, an unmet medical need exists, especially in severe gastrointestinal forms of aGVHD. We report the case of a 12-year-old male patient who developed severe gastrointestinal aGVHD after allo-HSCT for the treatment of high-risk acute myeloid leukemia. The grade IV aGVHD of the intestine showed no improvement under triple immunosuppression with corticosteroids, cyclosporine A and ruxolitinib. After receiving four weekly infusions of human allogeneic mesenchymal stromal cells DRK-BaW\u00fc-He-FFM (MSC-FFM), intestinal inflammation finally improved, as reflected by ameliorated symptoms, normalized intestinal wall thickness (ultrasonography) and decreasing calprotectin levels. Intestinal mucosal healing was further supported by a strict, formula-based modular diet. The present case supports efficacy and safety of MSC-FFM in combination with modular nutrition in complicated courses of aGVHD of the intestine refractory to multiple lines of therapy and introduces intestinal wall thickness and calprotectin levels as valuable markers of disease activity.<\/jats:p>","DOI":"10.1007\/s00277-025-06491-y","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T06:33:35Z","timestamp":1752561215000},"page":"4237-4243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment with mesenchymal stromal cells-Frankfurt am Main in a pediatric patient with steroid-refractory and ruxolitinib-refractory acute gastrointestinal graft-versus-host disease"],"prefix":"10.1007","volume":"104","author":[{"given":"Jana","family":"Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Reinsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Mentzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Milde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Gruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"1","key":"6491_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard F, Holler E, Sandmaier BM et al (2023) Acute graft-versus-host disease. Nat Rev Dis Primers 9(1):27. https:\/\/doi.org\/10.1038\/s41572-023-00438-1","journal-title":"Nat Rev Dis Primers"},{"key":"6491_CR2","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1182\/bloodadvances.2020003937","volume":"5","author":"N El Jurdi","year":"2021","unstructured":"El Jurdi N, Rayes A, MacMillan ML et al (2021) Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. Blood Adv 5:1352\u20131359. https:\/\/doi.org\/10.1182\/bloodadvances.2020003937","journal-title":"Blood Adv"},{"key":"6491_CR3","doi-asserted-by":"publisher","first-page":"9451950","DOI":"10.1155\/2018\/9451950","volume":"2018","author":"A Kuba","year":"2018","unstructured":"Kuba A, Raida L (2018) Graft versus host disease: from basic pathogenic principles to DNA damage response and cellular senescence. Mediators Inflamm 2018:9451950","journal-title":"Mediators Inflamm"},{"key":"6491_CR4","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1155\/2018\/9451950","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017) Acute Graft-versus-Host Disease - Biologic process, prevention, and therapy. N Engl J Med 377:2167\u20132179. https:\/\/doi.org\/10.1155\/2018\/9451950","journal-title":"N Engl J Med"},{"key":"6491_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood.2019000951","volume":"136","author":"C Voermans","year":"2020","unstructured":"Voermans C, Hazenberg MD (2020) Cellular therapies for graft-versus-host disease: a Tale of tissue repair and tolerance. Blood 136:410\u2013417. https:\/\/doi.org\/10.1182\/blood.2019000951","journal-title":"Blood"},{"issue":"11","key":"6491_CR6","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1097\/TP.0000000000001029","volume":"100","author":"JM Munneke","year":"2016","unstructured":"Munneke JM, Spruit MJ, Cornelissen AS et al (2016) The potential of mesenchymal stromal cells as treatment for severe Steroid-Refractory acute Graft-Versus-Host disease: A critical review of the literature. Transplantation 100(11):2309\u20132314. https:\/\/doi.org\/10.1097\/TP.0000000000001029","journal-title":"Transplantation"},{"key":"6491_CR7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00277-024-05952-0","volume":"104","author":"J Kujawska","year":"2025","unstructured":"Kujawska J, Zeiser R, Gil L (2025) Recent advances in acute Gastrointestinal graft versus host disease (aGVHD): aspects of steroid-resistant disease. Ann Hematol 104:855\u2013865. https:\/\/doi.org\/10.1007\/s00277-024-05952-0","journal-title":"Ann Hematol"},{"key":"6491_CR8","doi-asserted-by":"publisher","first-page":"1211171","DOI":"10.3389\/fimmu.2023.1211171","volume":"14","author":"C Luo","year":"2023","unstructured":"Luo C, Huang X, Wei L et al (2023) Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials. Front Immunol 14:1211171. https:\/\/doi.org\/10.3389\/fimmu.2023.1211171","journal-title":"Front Immunol"},{"issue":"17","key":"6491_CR9","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2020007336","volume":"136","author":"M Mohty","year":"2020","unstructured":"Mohty M, Holler E, Jagasia M et al (2020) Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood 136(17):1903\u20131906. https:\/\/doi.org\/10.1182\/blood.2020007336","journal-title":"Blood"},{"issue":"2","key":"6491_CR10","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M et al (2024) Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation. Lancet Haematol 11(2):e147\u2013e159. https:\/\/doi.org\/10.1016\/S2352-3026(23)00342-3","journal-title":"Lancet Haematol"},{"issue":"1","key":"6491_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S et al (2016) International, multicenter standardization of acute Graft-versus-Host disease clinical data collection: A report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transpl 22(1):4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"6491_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12967-023-04731-1","volume":"21","author":"H Bonig","year":"2023","unstructured":"Bonig H, Verbeek M, Herhaus P et al (2023) Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells Preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease. J Transl Med 21(1):837. https:\/\/doi.org\/10.1186\/s12967-023-04731-1","journal-title":"J Transl Med"},{"issue":"7","key":"6491_CR13","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41409-018-0102-z","volume":"53","author":"P Bader","year":"2018","unstructured":"Bader P, Ku\u00e7i Z, Bakhtiar S et al (2018) Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transpl 53(7):852\u2013862. https:\/\/doi.org\/10.1038\/s41409-018-0102-z","journal-title":"Bone Marrow Transpl"},{"key":"6491_CR14","unstructured":"European Medicines Agency EMA\/74208\/2022 Jakavi - EPAR (European Public Assessment Report): Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901\/2006; 16 Dec 2021"},{"key":"6491_CR15","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.4103\/REGENMED.REGENMED-D-24-00022","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J et al (2020) Ruxolitinib for Glucocorticoid-Refractory acute Graft-versus-Host disease. N Engl J Med 382:1800\u20131810. https:\/\/doi.org\/10.4103\/REGENMED.REGENMED-D-24-00022","journal-title":"N Engl J Med"},{"issue":"20","key":"6491_CR16","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood.2023022565","volume":"144","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Kang HJ, Bruno B et al (2024) Ruxolitinib for pediatric patients with treatment-na\u00efve and steroid-refractory acute graft-versus-host disease (REACH4). Blood 144(20):2095\u20132106. https:\/\/doi.org\/10.1182\/blood.2023022565","journal-title":"Blood"},{"issue":"4","key":"6491_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jtct.2024.01.080","volume":"30","author":"KN Ramos","year":"2024","unstructured":"Ramos KN, Leino D, Luebbering N et al (2024) Use of teduglutide in the management of Gastrointestinal Graft-versus-Host disease in children and young adults. Transpl Cell Ther 30(4):454.e1-454.e6","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"6491_CR18","doi-asserted-by":"publisher","first-page":"e30061","DOI":"10.1002\/pbc.30061","volume":"70","author":"G Aldouby Bier","year":"2023","unstructured":"Aldouby Bier G, Zaidman I, Dinur Schejter Y et al (2023) Vedolizumab for pediatric patients with Gastrointestinal acute graft-versus-host-disease. Pediatr Blood Cancer 70(1):e30061. https:\/\/doi.org\/10.1002\/pbc.30061","journal-title":"Pediatr Blood Cancer"},{"key":"6491_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjh.17700","volume":"195","author":"S Abedin","year":"2021","unstructured":"Abedin S, Rashid N, Schroeder M et al (2021) Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. Br J Haematol 195:429\u2013432. https:\/\/doi.org\/10.1111\/bjh.17700","journal-title":"Br J Haematol"},{"key":"6491_CR20","doi-asserted-by":"publisher","first-page":"839844","DOI":"10.3389\/fimmu.2022.839844","volume":"13","author":"O Ringd\u00e9n","year":"2022","unstructured":"Ringd\u00e9n O, Moll G, Gustafsson B et al (2022) Mesenchymal stromal cells for enhancing hematopoietic engraftment and treatment of Graft-Versus-Host disease, hemorrhages and acute respiratory distress syndrome. Front Immunol 13:839844. https:\/\/doi.org\/10.3389\/fimmu.2022.839844","journal-title":"Front Immunol"},{"key":"6491_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3324\/haematol.2015.140368","volume":"101","author":"Z Kuci","year":"2016","unstructured":"Kuci Z, Bonig H, Kreyenberg H et al (2016) Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease a multicenter survey. Haematologica 101:985\u2013994. https:\/\/doi.org\/10.3324\/haematol.2015.140368","journal-title":"Haematologica"},{"issue":"6","key":"6491_CR22","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/00054725-200606000-00013","volume":"12","author":"MR Konikoff","year":"2006","unstructured":"Konikoff MR, Denson LA (2006) Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 12(6):524\u2013534. https:\/\/doi.org\/10.1097\/00054725-200606000-00013","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"6491_CR23","doi-asserted-by":"publisher","first-page":"e4143","DOI":"10.7759\/cureus.4143","volume":"11","author":"MN Malik","year":"2019","unstructured":"Malik MN, Rafae A, Durer C et al (2019) Fecal calprotectin as a diagnostic and prognostic biomarker for Gastrointestinal graft versus host disease: A systematic review of literature. Cureus 11(2):e4143. https:\/\/doi.org\/10.7759\/cureus.4143","journal-title":"Cureus"},{"key":"6491_CR24","doi-asserted-by":"publisher","unstructured":"Vincent M, Assa A, Borrelli O et al (2025 May) Intestinal involvement in graft versus host disease in children: an overview by the ESPGHAN gastroenterology committee. J Pediatr Gastroenterol Nutr 29. https:\/\/doi.org\/10.1002\/jpn3.70087","DOI":"10.1002\/jpn3.70087"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06491-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06491-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06491-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:48:37Z","timestamp":1757663317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06491-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6491"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06491-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the parents of the child included in this study. Permission to publish the data has been taken from the parents of the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}